BioSpace News Archive

Ms. DeYoung joins Shattuck from ImmuneSensor Therapeutics, where she was the Chief Operating Officer responsible for corporate strategy, start-up operations, intellectual property, oversight of the Company’s first IND filing and the initiation of a first-in-human Phase 1 clinical trial.

Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the 38th Annual J.P. Morgan Healthcare Conference.

Australian life sciences company, QBiotics Group Limited (QBiotics) is today announcing the publication[1] of positive results from a first in-human Phase I clinical trial of its anticancer pharmaceutical, tigilanol tiglate (EBC-46) in EBioMedicine, a peer-reviewed translational biomedical research journal by The Lancet.

Comprehensive approach to project implementation and change management will lead to faster technology adoption and improved ROI

Medication intelligence software solution supports critical need for hospitals and health systems to identify drug diversion to combat national opioid crisis

A biosensor diagnostic company based in New York, GBS Inc. is commercializing the patent-protected Saliva Glucose Biosensor in the Asia Pacific region, where there are more people living with diabetes than anywhere else in the world.

Preclinical work is ongoing, with publication of initial data expected by mid-2020.

A team of medical experts from Israel’s Sheba Medical Center, Tel HaShomer is embarking on an emergency deployment to the Pacific island nation of Samoa following an urgent request from the World Health Organization (WHO) for humanitarian aid.

Proprietary triplet of U2 plus TG-1701 (BTK inhibitor) induced 86% ORR (6 of 7) in patients with relapsed/refractory NHL and CLL at the lowest dose of TG-1701 tested

Athira Pharma, Inc., a clinical-stage company developing innovative therapies focused on regeneration and recovery of brain function, today announced data from the randomized, placebo-controlled, double-blind Phase 1a/b clinical trial of NDX-1017 in 88 healthy subjects and patients with Alzheimer’s disease that were presented in an oral presentation at the 12th Annual Clinical Trials on Alzheimer’s Disease (CTAD)